Interleukin-18 for predicting the development of macrophage activation syndrome in systemic juvenile idiopathic arthritis

Bibliographische Detailangaben
Veröffentlicht in:	Clinical immunology (Orlando, Fla.). - 1999. - 160(2015), 2 vom: 14. Okt., Seite 277-81
1. Verfasser:	Shimizu, Masaki (VerfasserIn)
Weitere Verfasser:	Nakagishi, Yasuo, Inoue, Natsumi, Mizuta, Mao, Ko, Giyo, Saikawa, Yutaka, Kubota, Tomohiro, Yamasaki, Yuichi, Takei, Syuji, Yachie, Akihiro
Format:	Online-Aufsatz
Sprache:	English
Veröffentlicht:	2015
Zugriff auf das übergeordnete Werk:	Clinical immunology (Orlando, Fla.)
Schlagworte:	Journal Article Interleukin-18 (IL-18) Prediction of macrophage activation syndrome Systemic juvenile idiopathic arthritis IL6 protein, human Interleukin-18 Interleukin-6

Beschreibung
Zusammenfassung:	Copyright © 2015 Elsevier Inc. All rights reserved. To assess the role of IL-6/IL-18 in the pathogenesis of systemic juvenile idiopathic arthritis (s-JIA) and to investigate the clinical significance of serum IL-18 levels for predicting macrophage activation syndrome (MAS) development, we measured the serum IL-6/IL-18 levels in 76s-JIA patients, including 15 with MAS, and compared them with the clinical features. We identified 2 distinct subsets on the basis of serum IL-6/IL-18 levels. The IL-18-dominant subset had more patients who developed MAS. Serum IL-18 levels during active phase in patients with MAS were significantly higher than those without MAS. The cutoff value of serum IL-18 levels for predicting MAS development was 47750 pg/ml. The patients with IL-18 dominant subset at their disease onset were significantly more likely to develop MAS after TCZ therapy started. IL-18 might have a key role in the pathogenesis of MAS. Serum IL-18 levels >47750 pg/ml might be useful to predict MAS development
Beschreibung:	Date Completed 15.12.2015 Date Revised 10.03.2022 published: Print-Electronic Citation Status MEDLINE
ISSN:	1521-7035
DOI:	10.1016/j.clim.2015.06.005